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Introduction
Osteoarthritis (OA) is the most common form of
arthritis associated with significant morbidity, and is
one of the most common causes of functional limita-
tion and dependency. OA of the knee is characterized
by pain, stiffness, decreased joint range of motion and
increasing disability. It can have an impact on several
aspects of normal life, such as functional and social
activities, relationships, socioeconomic status, body
image, and emotional wellbeing.1–4 The earliest lesion
of OA is a diminution of mucopolysaccharide and
chondroitin sulfate relative to the collagen in the
matrix, thereby unmasking the collagen.1,5–7 For the
management of OA, it is important to prevent matrix
diminution early and induce matrix synthesis by
chondrocytes.
Hyaluronic acid (HA) is a major component of
synovial fluid and cartilage. HA plays many key roles
in the trophic status of the cartilage and in the regula-
tion of the intra-articular environment. HA is respon-
sible for the viscoelastic properties (shock-absorbing
and lubricating abilities) of synovial fluid, which has a
lower concentration and molecular weight in OA joints
than in healthy ones.8,9 HA can form a pericellular
coat around the cells, interact with proinflammatory
mediators, and bind to cell receptors to modulate cell
proliferation, migration, and gene expression.10–14
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The molecular weight of HA in the synovial fluid
of patients with RA is similar to that of patients with
other joint disease, and moderately but significantly
lower than that of normal synovial fluid.15 Serum HA
level is raised in patients with early RA and correlates
with clinical and laboratory measures of disease activ-
ity.16 The increase in serum HA probably reflects
excessive production by the rheumatoid synovium
and may serve as an index of inflammation.17,18
CD44 is a multistructural cell-surface glycoprotein
that interacts with many cell-surface and extracellular
ligands, the principal one being HA.19,20 Stimulation
of CD44 with HA transmits the signal into the cells,
which leads to activation of T cells and cytokine or
chemokine release from monocytes. CD44 is overex-
pressed in inflammatory sites in proportion to the
intensity of inflammation.20,21 CD44 expression is
markedly increased in lymphocytes from the synovial
fluid of RA patients.19,22 Arthritis of large joints (in
particular, the knee) at first presentation is associated
with a destructive course of RA.23
Increasing fibrin deposition is a predominant fea-
ture of RA in synovial tissue, and contributes to
chronic inflammation and progressive tissue abnor-
malities.24 Thrombin also acts as a mitogen to stimu-
late the abnormal proliferation of synovial cells during
RA pathogenesis.25 The inflamed RA synovium is
uniquely rich in free HA, which can block the ability
of antithrombin to inhibit thrombin, thus driving the
pathogenesis of thrombin-related RA.
Intra-articular treatment with HA for OA knee
pain is widely accepted. The efficacy and tolerability
with OA of the knee have been demonstrated in sev-
eral clinical trials.26–29 Inflammation of the knee joint
influences the excitability of the nociceptors of the
articular nerves. HA can decrease ongoing nerve activ-
ity as well as movement-evoked nerve activity.30 So the
therapeutic effect of HA for OA knee pain may be due
to the effect of HA on nerve impulses and nerve sensi-
tivity.3 HA administration can enhance the synthesis
of extracellular matrix proteins, including chondroitin,
keratin sulfate, and proteoglycans. Exogenous HA can
enhance endogenous HA synthesis.31
The aim of this study was to investigate the thera-




Inclusion criteria were: RA patient with significant
OA knee symptoms and signs; radiologically verified
knee OA (stage I–III according to the Kellgren-
Lawrence classification).27 Exclusion criteria were: a
significantly inflamed OA joint; previous intra-articular
injection of steroid or any other invasive procedure 
in the knee within the previous 6 months; history of
intra-articular knee fracture; any other condition that
might interfere with the efficiency assessment or trial
completion (such as the alternation of drugs for the
changing of RA activity).
Study design
All patients received intra-articular injection of HA
(ARTZ Dispo; 25 mg/2.5 mL) once a week for 5
weeks. During the study period, all patients did not
receive physical therapy for their OA knee problem. We
used the WOMAC (Western Ontario and McMaster
Universities) index28 to evaluate the therapeutic effects
at baseline (pre-injection), week 5 (after 5 courses of
injection) and week 9 (1 month after the last injec-
tion). The items on the WOMAC index included 3
dimensions—pain (5 questions), stiffness (2 questions)
and physical function subscales (17 questions)—and
were rated on an ordinal scale of 0 to 4. Lower scores
indicate lower levels of symptoms or physical disability.
The validation study reported internal consistencies
for the pain, stiffness and physical function subscales
of 0.86, 0.86 and 0.95, respectively.32 Reliability for
the pain, stiffness and physical function subscales were
0.68, 0.48 and 0.68, respectively.33
Statistical analysis
We used the Friedman test to evaluate the changes in
the WOMAC index among the 3 periods of the study.
If there was a significant difference (p < 0.05) among
the 3 periods, we used the Wilcoxon signed rank test
with Bonferroni correction method to identify which
2 periods were significantly different (p < 0.0167). In
addition, we used the Mann-Whitney U test to com-
pare differences in therapeutic effect.
Results
Twenty RA patients (1 male, 19 female; mean age,
52.6 years; age range, 32–72 years) with OA knees were
enrolled; 11 were placed into a stage II group and 9
were placed into a stage III group. The therapeutic
effect of intra-articular HA injection was significant 
at week 5 (p < 0.0167) and persisted to week 9 (p <
0.0167). There was no significant difference between
weeks 5 and 9; in each sub-item, the same results were
noted (Table 1). For subgroup evaluation, the thera-
peutic effect in the stage II and stage III groups were
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grossly of the same effectiveness but not significantly
different (p < 0.05 but not < 0.0167; Table 2) accord-
ing to the WOMAC index evaluation. There were no
significant differences between the groups with regard
to therapeutic effect (Table 3), and there were no
adverse effects during treatment.
Discussion
OA is not a simple wear-and-tear phenomenon, but is
an active process that is part of the reparative response
to injury.1 Ghosh and Guidolin34 found that HAs with
a molecular weight within the range of 0.5 × 106 to
1.0 × 106 Da (such as the ARTZ used in this study) are
generally more effective in reducing indices of synovial
inflammation and restoring the rheologic properties of
synovial fluid than HAs with a molecular weight of
more than 2.3 × 106 Da. Evidence of partial restoration
of normal joint tissue metabolism was noted in an ani-
mal model study.35 Intra-articular HA used for the treat-
ment of OA knee pain is a multifactorial mechanism.
HA can reduce the symptoms of OA by mitigating
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Table 1. Results of the Western Ontario and McMaster Universities Osteoarthritis Index*
Baseline Week 5 Week 9 p
23.5 (13.0–34.75) 11.0 (5.5–24.5) 10.0 (4.0–21.5) < 0.001
Week 5 vs. baseline: p < 0.001†
Week 9 vs. baseline: p < 0.001†
Week 9 vs. week 5: p = 0.121
Sub-items of WOMAC index in RA (n=20)
Pain 5.0 (3.0–7.0) 3.0 (1.0–5.75) 2.5 (0.25–5.75) < 0.001
Week 5 vs. baseline: p < 0.001†
Week 9 vs. baseline: p = 0.001†
Week 9 vs. week 5: p = 0.453
Stiffness 2.0 (1.0–3.75) 1.0 (0.0–2.0) 1.0 (0.0–1.75) < 0.001
Week 5 vs. baseline: p < 0.001†
Week 9 vs. baseline: p = 0.001†
Week 9 vs. week 5: p = 0.285
Physical function 17.0 (8.0–22.75) 9.0 (4.5–15.5) 6.0 (3.25–15.75) < 0.001
Week 5 vs. baseline: p < 0.001†
Week 9 vs. baseline: p < 0.001†
Week 9 vs. week 5: p = 0.208
*Data presented as median (interquartile range), Friedman test (p < 0.05); †Wilcoxon signed rank test with Bonferroni correction, p < 0.0167 is significant.
Table 2. Results of the Western Ontario and McMaster Universities Osteoarthritis Index in rheumatoid arthritis stages*
Baseline Week 5 Week 9 p
Stage II (n = 11) 20.0 (11.0–34.0) 10.0 (5.0–20.0) 9.0 (4.0–17.0) < 0.001
Week 5 vs. baseline: p = 0.003
Week 9 vs. baseline: p = 0.005
Week 9 vs. week 5: p = 0.66
Stage III (n = 9) 27.0 (17.5–41.5) 11.0 (7.5–30.0) 12.0 (4.5–37.0) 0.016
Week 5 vs. baseline: p = 0.007
Week 9 vs. baseline: p = 0.028
Week 9 vs. week 5: p = 0.722
*Data presented as median (interquartile range), Friedman test (p < 0.05). There was no significant difference by Wilcoxon signed rank test with Bonferroni
correction (p < 0.0167).
Table 3. Comparison of therapeutic effects between groups*
Stage II Stage III p
Baseline 20.0 (11.0–31.8) 27.0 (18.3–40.8) 0.183
Week 5 10.0 (5.5–19.3) 11.0 (8.8–28.0) 0.469
Week 9 9.0 (4.0–16.5) 12.0 (5.3–32.0) 0.361
*Data presented as median (interquartile range), Mann-Whitney U test.
the activities of proinflammatory mediators and pain-
producing neuropeptides released by activated syn-
ovial cells.1,3,34–36 The partially restored synovial fluid’s
rheologic properties and synovial fibroblast metabo-
lism in animal models were compatible with joint pain
reduction and improvement of functional status.36
Furthermore, the use of intra-articular HA injection
can delay the need for surgery in patients who are
candidates for total knee replacement.37
The most common adverse events that occur with
HA injection are local knee pain and/or swelling, which
were seen in 2.2% of injections, or in 7.2% of patients,38
but there were no local adverse events in our study.
The proinflammatory cytokines interleukin-1 and
tumor necrosis factor-α stimulate the expression of HA
synthetase,39 which may contribute to the fragmentation
of HA under inflammatory conditions. Fragmented
HA (< 500 kDa), rather than high-molecular-weight
HA (> 1 MDa),40 stimulates cell-surface CD44 recep-
tors, leading to intracellular signaling, gene activation
and the expression of proinflammatory mediators.
Low-molecular-weight fragments of HA also stimu-
late angiogenesis,41 an important factor in inflam-
mation. CD44 adhesion to HA has been shown to
mediate chondrocyte proliferation and function.42
Exogenous HA may facilitate the production of newly
synthesized HA.3,31
The rationale for intra-articular HA therapy (as in
our study) has been to replace degraded HA with
high-molecular-weight polysaccharide. The therapeu-
tic effect of injected high-molecular-weight HA may
be due to an increase in the local concentration, rather
than a major change in the molecular weight proper-
ties of the synovial polysaccharide. Systemic or local
steroid treatment, which is usually used for the man-
agement of RA, had no effect on the concentration or
molecular weight of HA.15 Corticosteroid seems to
be rather active in reducing the inflammatory process,
whereas HA seems to influence mostly the number
and distribution of lining cells and to stimulate the
reparative processes of OA.43 There is no evidence-
based therapeutic effect for combined therapy with
steroid and HA.
Pitsillides et al44 found that the ratio of free HA to
bound HA was significantly increased in RA. The high
concentration of free HA in diseased RA synovium
locally blocks antithrombin under physiologic condi-
tions and thereby deregulates the activity of throm-
bin.25 Some clinical studies have shown that injecting
HA into articular rheumatoid joints can ameliorate
inflammation.45,46 Determining the exact mechanism
by which HA inhibits antithrombin requires further
investigation.
Our study showed that intra-articular HA injec-
tion was beneficial in RA patients with OA knees. The
therapeutic effect is significant as evidence-based in
other OA knee patients (not under the influence of
stable RA itself). Though subgroup analysis (stage II
and stage III) showed no statistically significant dif-
ference, it may be due to the small sample size in each
group. This is the major limitation of our study.
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